Get the Stockscreener App
69.84
1.45%
1.00
After Hours:
69.84
Incyte Corp stock is traded at $69.84, with a volume of 1.49M.
It is up +1.45% in the last 24 hours and down -2.62% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$68.84
Open:
$68.58
24h Volume:
1.49M
Relative Volume:
0.73
Market Cap:
$13.45B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
36.95
EPS:
1.89
Net Cash Flow:
$16.80M
1W Performance:
+0.06%
1M Performance:
-2.62%
6M Performance:
+10.47%
1Y Performance:
+11.12%
1-Day Range:
$68.15
$70.19
1-Week Range:
$66.33
$70.19
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
69.84 | 13.45B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Franklin Resources Inc. Sells 50,188 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Sanctuary Advisors LLC Has $1.51 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Wells Fargo & Company Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com Australia
Insider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of Stock - MarketBeat
Incyte (NASDAQ:INCY) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Orion Portfolio Solutions LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Wellington Management Group LLP Has $4.74 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Toronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff as pipeline progress unfolds - Investing.com
Incyte (NASDAQ:INCY) Earns Outperform Rating from William Blair - MarketBeat
Vestcor Inc Has $174,000 Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Oppenheimer maintains $82 target on Incyte post-ASH updates - Investing.com
Incyte Co. (NASDAQ:INCY) Stake Boosted by National Bank of Canada FI - MarketBeat
Tri Ri Asset Management Corp Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Continuum Advisory LLC Cuts Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Tri Ri Asset Management Corp Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - MSN
Barclays PLC Boosts Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
Biotech Roundup: 3 Stocks to Watch - Schaeffers Research
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma - Yahoo Finance
Incyte reports positive Phase 3 data for Zynyz for lung cancer - MSN
Incyte (INCY) Stock Drops Amid Market Volatility - GuruFocus.com
Narrow-Moat Incyte's Hematology and Dermatology Platforms Drive Growth - Morningstar
Incyte reports positive Phase 3 data for Zynyz for lung cancer (NASDAQ:INCY) - Seeking Alpha
CURE Media Group announces winners of the 2024 MPN Heroes® Recognition Program - GlobeNewswire Inc.
Janus Henderson Group PLC Has $11.31 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
State Street Corp Sells 300,240 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Quantinno Capital Management LP Has $4.49 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Royal London Asset Management Ltd. Decreases Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte gains amid takeover speculation - MSN
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Jacobs Levy Equity Management Inc. Trims Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Fmr LLC - MarketBeat
Verition Fund Management LLC Buys Shares of 40,467 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Edgestream Partners L.P. Makes New Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Erste Asset Management GmbH Buys New Shares in Incyte Co. (NASDAQ:INCY) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):